Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
NEW HAVEN, Conn., March 03, 2016 -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will present a clinical and corporate update at BioCentury’s 23rd annual Future Leaders in the Biotech Industry conference at 11:30 a.m. ET on March 11, 2016. The conference is being held at the Millennium Broadway Hotel & Conference Center in New York City, NY.
The Future Leaders in the Biotech Industry conference connects Wall Street and pharmaceutical executives with private and public biotechnology companies, offering new investment and partnering opportunities. Last year, more than 500 delegates, representing top financial institutions, pharmaceutical business development executives, and high net worth investors congregated at Future Leaders. For more information, or to request a one-on-one meeting with Melinta, please visit: http://www.biocentury.com.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development of novel antibiotics that provide new and better therapeutic solutions. Melinta is rapidly progressing its late-stage investigational antibiotic, Baxdela, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Melinta is committed to developing, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), which cause the majority of life-threatening hospital infections.
Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners (www.vaterahealthcare.com) and Malin Corporation plc (www.malinplc.com) among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL. Visit www.melinta.com for more information.
Melinta Therapeutics Kathy Powell (312) 724-9400 [email protected] Media Contact Aline Sherwood (312) 238-8957 [email protected]
